company background image
IMMU

Mendus OM:IMMU Stock Report

Last Price

kr1.85

Market Cap

kr368.5m

7D

-3.5%

1Y

-56.0%

Updated

26 Sep, 2022

Data

Company Financials +
IMMU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

IMMU Stock Overview

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer.

Mendus AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mendus
Historical stock prices
Current Share Pricekr1.85
52 Week Highkr6.34
52 Week Lowkr1.75
Beta0.79
1 Month Change-20.69%
3 Month Change-15.03%
1 Year Change-56.00%
3 Year Change-72.94%
5 Year Change-86.75%
Change since IPO-78.26%

Recent News & Updates

Aug 10
Is Mendus (STO:IMMU) Using Debt Sensibly?

Is Mendus (STO:IMMU) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

May 10
Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

IMMUSE BiotechsSE Market
7D-3.5%-8.5%-5.5%
1Y-56.0%-39.5%-30.2%

Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned -40.6% over the past year.

Return vs Market: IMMU underperformed the Swedish Market which returned -30.2% over the past year.

Price Volatility

Is IMMU's price volatile compared to industry and market?
IMMU volatility
IMMU Average Weekly Movement6.1%
Biotechs Industry Average Movement8.1%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.5%
10% least volatile stocks in SE Market4.3%

Stable Share Price: IMMU is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: IMMU's weekly volatility has decreased from 11% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200234Erik Mantinghttps://www.mendus.com

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company’s products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers.

Mendus AB (publ) Fundamentals Summary

How do Mendus's earnings and revenue compare to its market cap?
IMMU fundamental statistics
Market Capkr368.49m
Earnings (TTM)-kr116.61m
Revenue (TTM)kr1.80m

204.9x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMMU income statement (TTM)
Revenuekr1.80m
Cost of Revenuekr0
Gross Profitkr1.80m
Other Expenseskr118.41m
Earnings-kr116.61m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 11, 2022

Earnings per share (EPS)-0.58
Gross Margin100.00%
Net Profit Margin-6,478.28%
Debt/Equity Ratio6.5%

How did IMMU perform over the long term?

See historical performance and comparison